New Supply Agreements and Analytical Tools, Expansions, Conference Presentations and Financial Results - Research Report on WuXi PharmaTech, Sirona, ICON, Opexa Therapeutic and Karyopharm Therapeutics PR Newswire NEW YORK, November 20, 2013 NEW YORK, November 20, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting WuXi PharmaTech (Cayman) Inc. (NYSE: WX), Sirona Dental Systems Inc. (NASDAQ: SIRO), ICON plc (NASDAQ: ICLR), Opexa Therapeutics, Inc. (NASDAQ: OPXA) and Karyopharm Therapeutics, Inc. (NASDAQ: KPTI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. WuXi PharmaTech (Cayman) Inc. Research Report On November 15, 2013, WuXi PharmaTech (Cayman) Inc. (WuXi PharmaTech) announced that its wholly owned subsidiary Shanghai SynTheAll (STA) Pharmaceutical Co., Ltd., has entered into a supply arrangement with Pharmacyclics, Inc. The Company said that this follows a successful multiple-year development and clinical manufacturing partnership that supported Pharmacyclics with the expedited New Drug Application submission and final approval by the US Food & Drug Administration (FDA). Further, WuXi PharmaTech said that after an expedited review by the FDA, IMBRUVICA received approval on November 13, 2013, for treatment of patients with mantle cell lymphoma who have received at least one prior therapy. According to the Company, IMBRUVICA is a first-in-class, oral therapy which has been granted three Breakthrough Therapy Designations by the FDA, a first for an oncology drug. These designations are intended to expedite the development and review of drugs for serious or life-threatening conditions. The Full Research Report on WuXi PharmaTech (Cayman) Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/df7b_WX Sirona Dental Systems Inc. Research Report On November 11, 2013, Sirona Dental Systems Inc. (Sirona) announced that it has increased its footprint in the Asia-Pacific region by establishing a subsidiary in Singapore. According to Company, the new Sirona facilities, spanning 3,445 square feet, accommodate a fully equipped showroom and training facilities, as well as offices for the team. Sirona Singapore will start with a team of six employees in sales, service, logistics & operations and finance, as well as product specialists and looks forward to quickly expanding to full size. The Company informed that Sirona Singapore is based at six Battery Road, in the heart of Singapore City, within walking distance of Marina Bay. The Full Research Report on Sirona Dental Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/08e7_SIRO ICON plc Research Report On November 13, 2013, ICON plc (ICON) announced the launch of ICONIK Labs- an interactive analytics tool that allows Clinical and Medical team members to visualize, analyze and report on large volumes of laboratory data in real time - the Company's latest service to leverage its ICONIK technology platform. Using ICONIK Labs' advanced visualization capabilities, project teams can interact with data and view trends at any level of detail, including patient, site, study or across an entire program through a series of dynamic filters. According to ICON, ICONIK Labs enhances a study's quality by instantly identifying sites with an unusual number of lab values outside the normal range and can also improve patient safety by providing Hy's Law analysis which assists with the detection of subjects at risk of Drug Induced Liver Injury (DILI). The Full Research Report on ICON plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/fbb0_ICLR Opexa Therapeutics, Inc. Research Report On November 7, 2013, Opexa Therapeutics, Inc. (Opexa Therapeutics) reported its financial results for Q3 2013, with revenues of $0.3 million, compared with nil in Q3 2012. Net loss came in at $5.7 million or $0.39 per basic and diluted share, compared to net loss of $2.4 million, or $0.40 per diluted share in Q3 2012. Commenting on the results, President and CEO Neil K. Warma said, "We recently reached a major milestone by enrolling the 100th patient into the Abili-T study. With the recent addition of three new clinical trial sites in the U.S., we now have 33 centers across North America participating in the Abili-T study," added Mr. Warma. "We expect to complete enrollment of 180 patients in early 2014 and release the top-line results of the study in the middle of 2016." The Full Research Report on Opexa Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/a67b_OPXA Karyopharm Therapeutics, Inc. Research Report On November 8, 2013, Karyopharm Therapeutics, Inc. (Karyopharm) announced the presentation of several studies at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held from December 7, 2013 to December 10, 2013 at the Ernest N. Morial Convention Center in New Orleans, LA. "We are excited to present data from multiple studies at ASH and to discuss Selinexor," commented Sharon Shacham, Ph.D., Founder, Chief Scientific Officer and President of Research and Development of Karyopharm. The Full Research Report on Karyopharm Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/35cc_KPTI EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.analystscorner.com/ SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
New Supply Agreements and Analytical Tools, Expansions, Conference Presentations and Financial Results - Research Report on WuXi
Press spacebar to pause and continue. Press esc to stop.